Ethanol metabolism results in a G2/M cell-cycle arrest in recombinant Hep G2 cells.
Previous studies using the Hep G2-based VA cells showed that ethanol metabolism resulted in both cytotoxicity and impaired DNA synthesis, causing reduced accumulation of cells in culture. To further characterize the ethanol oxidation-mediated impairment of DNA synthesis we analyzed the cell-cycle progression of VA cells. These studies showed approximately a 6-fold increase in the percentage of cells in the G2/M phase of the cell cycle after 4 days of ethanol exposure. The G2/M transition requires activity of the cyclin-dependent kinase, Cdc2. Cdc2 is positively regulated by association with cyclin B1, and negatively regulated by phosphorylation of amino acids Thr14 and Tyr15. Immunoblot analysis revealed that ethanol metabolism had little affect on total Cdc2 content in these cells, but resulted in the accumulation of up to 20 times the amount of cyclin B1, indicating that cyclin B1 was available for formation of Cdc2/cyclin B1 complexes. Co-immunoprecipitation revealed that 6 times more Cdc2/cyclin B1 complexes were present in the ethanol-treated cells compared with the controls. Investigation of the phosphorylation state of Cdc2 revealed that ethanol oxidation increased the amount of the phosphorylated inactive form of Cdc2 by approximately 3-fold. Thus, the impairment in cell-cycle progression could not be explained by a lack of cyclin B1, or the ability of Cdc2 and cyclin B1 to associate, but instead resulted, at least in part, from impaired Cdc2 activity. In conclusion, ethanol oxidation by VA cells results in a G2/M cell-cycle arrest, mediated by accumulation of the phosphorylated inactive form of Cdc2.
Clemens
Dahn L
DL
Department of Internal Medicine, University of Nebraska Medical Center and Veterans Administration Medical Center, Omaha, NE 68105, USA. dclemens@unmc.edu
Calisto
Lilian E
LE
Sorrell
Michael F
MF
Tuma
Dean J
DJ
D000426:Alcohol Dehydrogenase / Q000235:genetics / Q000378:metabolism; D016203:CDC2 Protein Kinase / Q000378:metabolism; D006528:Carcinoma, Hepatocellular; D002455:Cell Division / Q000187:drug effects; D002492:Central Nervous System Depressants / Q000493:pharmacokinetics*; D016213:Cyclins / Q000378:metabolism; D000431:Ethanol / Q000493:pharmacokinetics*; D016195:G2 Phase / Q000187:drug effects; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D006801:Humans; D008113:Liver Neoplasms; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects; D010766:Phosphorylation; D011994:Recombinant Proteins / Q000235:genetics; D014162:Transfection; D014407:Tumor Cells, Cultured
D002492:Central Nervous System Depressants; D016213:Cyclins; D011994:Recombinant Proteins; D000431:Ethanol; D000426:Alcohol Dehydrogenase; D016203:CDC2 Protein Kinase; D020928:Mitogen-Activated Protein Kinases